A detailed history of First Trust Advisors LP transactions in Vericel Corp stock. As of the latest transaction made, First Trust Advisors LP holds 31,918 shares of VCEL stock, worth $1.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,918
Previous 91,750 65.21%
Holding current value
$1.8 Million
Previous $4.21 Million 67.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$42.25 - $53.56 $2.53 Million - $3.2 Million
-59,832 Reduced 65.21%
31,918 $1.35 Million
Q2 2024

Aug 13, 2024

BUY
$41.71 - $52.9 $2.29 Million - $2.91 Million
55,006 Added 149.7%
91,750 $4.21 Million
Q1 2024

May 13, 2024

SELL
$32.52 - $52.33 $680,546 - $1.1 Million
-20,927 Reduced 36.29%
36,744 $1.91 Million
Q4 2023

Feb 13, 2024

SELL
$30.85 - $37.09 $678,545 - $815,794
-21,995 Reduced 27.61%
57,671 $2.05 Million
Q3 2023

Nov 13, 2023

BUY
$31.69 - $39.25 $1.33 Million - $1.65 Million
41,979 Added 111.39%
79,666 $2.67 Million
Q2 2023

Aug 14, 2023

BUY
$29.0 - $38.37 $224,634 - $297,214
7,746 Added 25.87%
37,687 $1.42 Million
Q1 2023

May 15, 2023

BUY
$23.85 - $31.34 $714,092 - $938,350
29,941 New
29,941 $877,000
Q3 2022

Nov 14, 2022

SELL
$22.62 - $32.54 $501,055 - $720,793
-22,151 Reduced 66.55%
11,134 $258,000
Q2 2022

Aug 12, 2022

BUY
$22.88 - $39.45 $524,157 - $903,760
22,909 Added 220.79%
33,285 $838,000
Q1 2022

May 13, 2022

SELL
$31.69 - $43.29 $724,528 - $989,739
-22,863 Reduced 68.78%
10,376 $397,000
Q4 2021

Feb 08, 2022

SELL
$35.2 - $52.6 $1.08 Million - $1.62 Million
-30,709 Reduced 48.02%
33,239 $1.31 Million
Q3 2021

Nov 15, 2021

SELL
$46.35 - $59.75 $2 Million - $2.57 Million
-43,096 Reduced 40.26%
63,948 $3.12 Million
Q2 2021

Aug 16, 2021

BUY
$47.2 - $67.81 $5.05 Million - $7.26 Million
107,044 New
107,044 $5.62 Million

Others Institutions Holding VCEL

About Vericel Corp


  • Ticker VCEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,178,000
  • Market Cap $2.67B
  • Description
  • Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for t...
More about VCEL
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.